Breast cancer: a new treatment avenue identified at the CRCHUM and the Peter MacCallum Cancer Centre

MONTREAL, May 17 /CNW Telbec/ - Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells. Over the past few years Herceptin® (trastuzumab) has become the standard treatment for this kind of cancer. While it is known that it blocks the activity of this protein, its exact mechanism of action has remained a mystery.

Professor John Stagg, a CRCHUM researcher, Professor Mark J. Smyth, with the Peter MacCallum Cancer Centre in Australia, and their colleagues* have discovered that in addition to blocking cell proliferation, Herceptin also stimulates the production of interferons, which in turn activate immune cells called lymphocytes.

For a full version of the press release: www.chumtl.qc.ca/presse.fr.html

SOURCE CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

For further information:

For more information and to obtain a copy of the study:
Lucie Dufresne
Communication Officer
Centre hospitalier de l'Université de Montréal
+ 1 514-890-8000, extension 15380
Pager: + 1 514-860-7110
lucie.dufresne.chum@ssss.gouv.qc.ca

Organization Profile

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890